安图生物
(603658)
| 流通市值：191.83亿 | | | 总市值：191.83亿 |
| 流通股本：5.71亿 | | | 总股本：5.71亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 992,202,191.51 | 4,226,413,277.24 | 3,127,156,171.6 | 2,060,307,179.95 |
| 营业收入 | 992,202,191.51 | 4,226,413,277.24 | 3,127,156,171.6 | 2,060,307,179.95 |
| 二、营业总成本 | 758,254,185.72 | 3,171,017,904.49 | 2,294,860,260.37 | 1,506,453,270.45 |
| 营业成本 | 330,992,970.52 | 1,452,300,743.96 | 1,099,754,181.57 | 732,834,381.85 |
| 税金及附加 | 15,916,555.61 | 62,570,065.66 | 43,820,703.41 | 27,676,624.21 |
| 销售费用 | 198,459,731.57 | 850,346,611.64 | 588,929,376.21 | 389,039,334.86 |
| 管理费用 | 70,708,301.98 | 241,291,919.7 | 163,164,328.7 | 102,288,423.93 |
| 研发费用 | 134,113,720.19 | 555,115,864.12 | 392,925,176.19 | 250,345,849.36 |
| 财务费用 | 8,062,905.85 | 9,392,699.41 | 6,266,494.29 | 4,268,656.24 |
| 其中:利息费用 | 2,725,390.3 | 13,958,489.76 | 11,878,575.69 | 9,517,542.81 |
| 其中:利息收入 | 3,584,259.67 | 7,079,028.42 | 4,280,372.11 | 2,480,460.15 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,201,247.29 | -3,495,613.67 | -2,656,044.42 | -54,112.42 |
| 加:投资收益 | 19,877,467.29 | 104,506,851.42 | 86,016,772.34 | 67,250,439.05 |
| 资产处置收益 | - | 637,786.38 | -3,315.41 | 38,609.84 |
| 资产减值损失(新) | 1,699,906.84 | -19,708,750.29 | -12,967,991.55 | -14,215,837.01 |
| 信用减值损失(新) | -2,867,259.07 | -8,950,967.28 | -4,405,590.05 | 1,913,032 |
| 其他收益 | 8,894,839.76 | 89,544,334.04 | 53,916,907.55 | 28,025,398.61 |
| 四、营业利润 | 262,754,207.9 | 1,217,929,013.35 | 952,196,649.69 | 636,811,439.57 |
| 加:营业外收入 | 1,055,929.03 | 20,022,116.23 | 18,307,958.53 | 9,879,032.7 |
| 减:营业外支出 | 1,823,377.28 | 15,184,737.02 | 11,330,294.22 | 7,845,037.1 |
| 五、利润总额 | 261,986,759.65 | 1,222,766,392.56 | 959,174,314 | 638,845,435.17 |
| 减:所得税费用 | 22,849,481.09 | 136,382,170.51 | 86,449,225.68 | 60,808,445.42 |
| 六、净利润 | 239,137,278.56 | 1,086,384,222.05 | 872,725,088.32 | 578,036,989.75 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 239,137,278.56 | 1,086,384,222.05 | 872,725,088.32 | 578,036,989.75 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 236,447,362.38 | 1,068,016,468.23 | 859,515,131.82 | 571,001,185.83 |
| 少数股东损益 | 2,689,916.18 | 18,367,753.82 | 13,209,956.5 | 7,035,803.92 |
| 扣除非经常损益后的净利润 | 232,433,248.15 | 998,383,780.15 | 815,477,646.46 | 546,316,646.83 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.41 | 1.87 | 1.5 | 1.02 |
| (二)稀释每股收益 | 0.41 | 1.87 | 1.5 | 1.02 |
| 八、其他综合收益 | -160,461.9 | -195,065.28 | -84,048.63 | -8,422.01 |
| 归属于母公司股东的其他综合收益 | -160,461.9 | -195,065.28 | -84,048.63 | -8,422.01 |
| 九、综合收益总额 | 238,976,816.66 | 1,086,189,156.77 | 872,641,039.69 | 578,028,567.74 |
| 归属于母公司股东的综合收益总额 | 236,286,900.48 | 1,067,821,402.95 | 859,431,083.19 | 570,992,763.82 |
| 归属于少数股东的综合收益总额 | 2,689,916.18 | 18,367,753.82 | 13,209,956.5 | 7,035,803.92 |
| 公告日期 | 2026-04-23 | 2026-04-23 | 2025-10-30 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |